Comparison of Liquid-Liquid Extraction and Solid Phase Extraction of Mephedrone by Love, Brittany Simone
The University of Southern Mississippi 
The Aquila Digital Community 
Master's Theses 
Spring 2013 
Comparison of Liquid-Liquid Extraction and Solid Phase 
Extraction of Mephedrone 
Brittany Simone Love 
University of Southern Mississippi 
Follow this and additional works at: https://aquila.usm.edu/masters_theses 
 Part of the Chemistry Commons, and the Forensic Science and Technology Commons 
Recommended Citation 
Love, Brittany Simone, "Comparison of Liquid-Liquid Extraction and Solid Phase Extraction of 
Mephedrone" (2013). Master's Theses. 406. 
https://aquila.usm.edu/masters_theses/406 
This Masters Thesis is brought to you for free and open access by The Aquila Digital Community. It has been 
accepted for inclusion in Master's Theses by an authorized administrator of The Aquila Digital Community. For 
more information, please contact Joshua.Cromwell@usm.edu. 
The University of Southern Mississippi 
COMPARISON OF LIQUID-LIQUID EXTRACTION AND SOLID PHASE 
EXTRACTION OF MEPHEDRONE 
by 
Brittany Simone Love 
A Thesis 
Submitted to the Graduate School 
of The University of Southern Mississippi 
in Partial Fulfillment of the Requirements 
for the Degree of Master of Science 
Approved: 
 
 
May 2013 
ABSTRACT 
COMPARISON OF LIQUID-LIQUID EXTRACTION AND SOLID PHASE 
EXTRACTION OF MEPHEDRONE 
by Brittany Simone Love 
May 2013 
Legal high drugs are modified scheduled drugs. As with any new drug, 
researchers have to conduct studies to gather information about the drug. The problem 
with obtaining accurate information on new drugs is that by the time information is 
gathered, drug abusers and street chemists have developed new ones. Comparing 
designer drugs to their illegal counterparts is often helpful in that it can provide a starting 
point. Mephedrone is a new designer drug that has become a problem over the past few 
years. Often marketed as bath salts and plant food, mephedrone has become the 
knockoff replacement for amphetamines. 
This experiment focused on comparing liquid-liquid extraction to solid phase 
extraction to determine if there was a difference and which was more efficient. Synthetic 
urine samples were spiked with mephedrone, extracted using both methods, and analyzed 
with GC-MS. Spiked synthetic urine samples were also analyzed to determine the limit 
of detection for mephedrone. 
A T-ratio test determined that there is less than a 5% chance that LLE and SPE 
are the same for extracting mephedrone. The t ratios for extracting 0.5µg/mL via LLE 
and SPE were 5.567 and 6.542, which were above the level of significance t value 2.086. 
After determining that the methods were statistically different, the percent recovery of 
each method was observed. The percent recovery of SPE was higher than that of LLE for 
11 
0.5µg/mL, making SPE the better method. For 2.0µg/mL SPE percent recovery was less 
than LLE, proving LLE to be better in this case. 
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CHAPTER I 
INTRODUCTION 
Designer Drugs 
Various drug regulations continue to stir up conflict within a society of drug 
abusers. As a result, these abusers have found ways to avoid the consequences of law 
while simultaneously acquiring the drugs they desire. These altered substances, 
commonly known as designer drugs, are formulated to bypass the laws that prohibit their 
counterparts while mimicking similar effects. Because many designer drugs are not 
controlled under the Controlled Substances Act, they are referred to as Legal highs, but 
are still considered to be drugs of abuse. Most of these drugs are controlled under the 
Federal Analog Act of Controlled Substances Act due to their being derived from other 
controlled substances (Drugs of Abuse, 2011). 
Due to the lack of availability and purity of common drugs of abuse, clandestine 
laboratories began producing and selling mephedrone. Mephedrone is a synthetic 
derivative of cathinone, an active ingredient found in Khat (Drugs of Abuse, 2011 ). Also 
known as plant food or bath salts and often sold online labeled "not for human 
consumption," mephedrone has become the new drug of choice and interest. The recent 
spark of mephedrone use appears to have originated primarily in the United Kingdom and 
eventually began to make headlines in the United States. With increasing popularity and 
emergency room reports, there have been numerous case studies on mephedrone to 
determine its effects and toxicity. Although mephedrone has now been scheduled under 
the Controlled Substances Act as a Schedule I drug, there is still much to be known about 
this designer drug. 
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Development of methods for analyzing designer drugs is crucial to the discipline 
of toxicology. Effective extraction methods, analysis, and toxic research play a huge role 
in keeping up with the constantly growing and changing drug field. Just as easily as 
ecstasy and amphetamines were replaced with mephedrone, mephedrone will be replaced 
with another designer drug. The challenge with developing methodologies for designer 
drugs is there is usually no previous or current data on the drug. Without established 
knowledge or reference standards to compare to, analysts seem to fall a step behind 
clandestine laboratories. Research on methods, such as extractions, is beneficial in that it 
can cut down on time that is spent on methods and techniques that are not productive. 
For the determination of mephedrone toxicity, sample preparations as well as 
proper extraction methods from biological fluids are an important factor. Extractions 
have a direct effect on the sensitivity and quantization of drug analysis. An efficient 
method of extraction should possess high recovery and reproducibility. Extractions are 
the transfer of an analyte from one miscible phase to another phase and are used to 
separate the analyte from mediums such as blood, urine, or bile (Harris, 2007). Based 
around pH and polarity, a drug's pKa is one of the determining factors for choosing an 
extraction solvent that the analyte can be partitioned in. The pKa is the negative 
logarithm of an acid dissociation constant and describes how an acid ionizes in solution 
(Harris, 2007). If the pKa is small, the acid is completely ionized and is a strong acid. A 
large pKa correlates to a weak acid, meaning that the acid is partially ionized. The 
Henderson-Hasselbach equation is used to determine an analyte's pH by expressing the 
ratio of ionized to unionized ions in relation to its pKa. 
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Before a drug can be analyzed, it has to be removed from its matrix. Liquid-
liquid extractions and solid phase extractions are the most commonly used methods to 
separate a drug from its matrix. Liquid-liquid extraction (LLE) is the use of two 
immiscible liquids to extract a drug of interest in a liquid in which it is miscible. 
Depending on the drug's pKa, a buffer is added to the matrix to convert the drug to its 
unionized form. Once in its unionized form, the drug can be separated from the matrix 
with the addition of an extraction solvent that is polar enough to extract the drug of 
interest. After the solvent is allowed to mix with the sample, the sample is centrifuged to 
separate the organic solvent from the aqueous layer. The volatile organic extract is 
removed and allowed to dry, leaving only the drug of interest behind. Now that the drug 
has been isolated, it can be analyzed. 
Solid phase extractions (SPE) use columns with a stationary phase to trap the drug 
of interest while separating it from its matrix. The same concept with LLE of pH and 
pKa drive the separating factors of SPE, except that SPE contains an absorbent solid. The 
solid phase is made of sorbent silica that has an affinity for the drug of interest, binding 
it, while allowing unwanted waste materials to pass by. Before separating the drug from 
its matrix, the columns are conditioned with methanol (MeOH) and water to remove 
absorbed organic material in the column. The sample containing the drug of interest is 
poured into the column allowing the drug to adhere to the stationary phase. Columns 
have different types of systems to help materials pass through the column; there are 
columns that allow the materials to flow by gravity, or with negative or positive pressure 
systems. Once the drug is contained in the column, the sample is washed with weak 
solvents and water to removed unwanted polar solutes. A strong organic solvent is used 
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to elute the strongly bound drug from the stationary phase. The desired eluent is eluted in 
its own tube and evaporated to dryness, leaving only the drug. 
In some cases, an additional step of derivatization is beneficial before the analysis 
of the isolated drug. Derivatization is the process of chemically altering an analyte to 
make it easier to detect or separate (Harris, 2007). Derivatization is used in this study to 
improve the analyte's chromatographic behavior and assure its identification. Most 
commonly used derivatizing reagents are bistrimethylsilyltrifluoroacetamide (BSTFA), 
heptafluorobutyric anhydride (HFBA), pentafluoropropionic anhydride (PFPA), and 
trifluoroacetic anhydride (TFAA). A study conducted by Cerilliant (2011) determined 
that TFAA is the best derivatizing reagent to use with designer drugs such as 
mephedrone. 
In studies conducted on mephedrone, both methods have been used, but there 
has been no specification of which is more conducive for the analysis of mephedrone. 
The efficiency of either extraction method can be measured via analysis of mephedrone 
with gas chromatography with mass spectrometric detection (GC-MS). GC-MS assays 
can provide spectral analysis on mephedrone spiked synthetic urine samples. The 
spectrum will provide information about the recovery of the extraction and detection 
limits. 
CHAPTER II 
REVIEW OF LITERATURE 
Liquid-Liquid Extraction 
5 
Every step of drug analysis is critical, but preparation of the sample for analysis is 
the most crucial part to achieving valid results. "Sample preparation is the series of steps 
required to transform a sample so that it is suitable for analysis" (Harris, 2007, p. 655). 
Sample preparation can consist of extraction of the desired drug from its matrix, making 
the sample more concentrated so that it can be detected, or just dissolving the sample. 
Extraction involves the dissolving of an analyte in a solvent without affecting the drug of 
interest (Harris, 2007). Analysts attempt to control which direction the analysis can go 
with each step they take in preparing the sample for analysis. 
Liquid-liquid extraction, LLE, is the most commonly used method of extraction 
because it is direct and blood and urine are the specimens that are frequently tested for 
the determination of drugs. Because blood and urine are liquids, they are easily 
"partitioned with an organic solvent without protein precipitation after a pH adjustment 
of the liquid with a buffer, acid, or base" (Siek, 2010, p. 71 ). Polarity is the deciding 
factor behind choosing an organic solvent for extraction of drugs. After deciding on the 
proper organic solvent to use, a buffer is sometimes added so the drug of interest will be 
in its non-ionic form and easily partition into the organic solvent of choice. The 
adjustment of the pH before extraction depends on what class the drug falls in. Drugs are 
classified into six classes: strong acids, weak acids, neutrals, weak bases, strong bases, 
and amphoteric bases. When performing chromatographic assays such as HPLC, TLC, 
or GC, samples have to be extracted twice in order to have an extract that can be 
chromatographed (Siek, 2010). 
Solid Phase Extraction 
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To overcome the disadvantages of LLE, another method of extraction exists, solid 
phase extraction. Harris (2007) describes solid phase extraction as a process in which a 
solution is passed through a short column of chromatographic stationary phase to separate 
the analyte from the matrix and the absorbed analyte on the column is eluted from the 
column with a solvent. This method of separation is recorded to have existed since the 
biblical days but has only been of scientific value and used as a technique since the 1970s 
(Simpson, 2000). 
The most important part in solid phase separation is the column. Columns were 
developed in the 1960s and early '70s by bench toxicologists who developed their own 
columns for separation (Siek, 2010). These columns contained sodium sulfate to absorb 
water and shredded filter paper or cotton to retain the desired drug (Siek, 2010). This 
somewhat successful method involved pouring blood through the column and afterwards 
pouring a solvent through to recover the drug of interest (Siek, 2010). In October of 
1977, the process became more convenient with the development of prepackaged, 
disposable columns with bonded silica sorbents (Simpson, 2000). 
The objective of solid phase extraction is for the analyte to be concentrated, 
cleaned of unwanted molecules, and/or separated from the matrix (Simpson, 2000). An 
isolated, cleaned, and concentrated drug is achieved through three steps. The first step is 
retention, in which the analyte is separated from the matrix and retained by the sorbent 
particles in the column. After retention of the analyte to the column, the column is 
washed with a solvent to remove any interfering compounds that can affect analysis. 
Finally the analyte is eluted from the column with the passing of a solvent to desorb the 
analyte and collect it in the solvent (Simpson, 2000). 
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Developed to overcome the challenges with liquid-liquid extraction, solid phase 
extraction has its own disadvantages as well. In the case of drugs like benzodiazepines 
and tricyclics, solid phase extraction uses more solvents, materials, and time. Although 
this method is more tedious than liquid-liquid extraction, it compensates for that with its 
reproducibility and minimizing the use of solvents (Siek, 2010). Unlike liquid-liquid 
extractions that have to use immiscible solvents for the sample, solid phase extraction can 
use miscible solvents (Simpson, 2000). 
Mephedrone 
Mephedrone has become an increasing problem in recent years, along with other 
designer drugs. These designer drugs are synthetically made to possess similar effects to 
the drugs from which they are derived while bypassing the laws that legally prohibit their 
counterparts. Mephedrone (4-methylmethcathinone, 4-MMC) is a psychoactive 
derivative of cathinone that provides similar results to those of stimulant and 
hallucinogenic drugs. Cathinone is a naturally occurring alkaloid of the Khat plant, 
Catha edulis, which originates in Northeast Africa and the Arabian Peninsula (National 
Drug Intelligence Center, 2003). The derivatives of cathinones are the P-keto analogues 
of the phenethylamine family (Drug Profiles, 2012). 
Mephedrone is a ring substituted cathinone that differs from its phenethylamine 
counterparts "by a keto functional group at the beta carbon" (Sedefov & Gallegos, 2011, 
p. 27). Systematically named by IUPAC as (RS)-2-methylamino-l-( 4-
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methylphenyl)propan-1-one, mephedrone's molecular formula, molecular weight, boiling 
point, and melting point are: C11H15NO, l77.242g/mol, 269.51°C, and 66.61 °C 
respectively (Sedefov & Gallegos, 2011). 
Cathinone Mephedrone Amphetamine Phenethylamine 
Figure 1. Mephedrone and its related structures 
Sedefov and Gallegos (2011) report that mephedrone was mentioned as early as 
1929 by Saem de Bumaga Sanchez, who described its synthesis, mentioning it as toluyl-
alpha-monomethylaminoethylcetone. The straightforward synthesis of mephedrone 
combines the product of brominated 4-methylpropiophenone with methyl amine and an 
acid scavenger. Gaseous or aqueous hydrochloride is then added to provide the 
hydrochloride salt that will need to be recrystallized. Mephedrone can also be 
synthesized from the oxidation of 4-methylephedrine with potassium permanganate or 
potassium dichromate (Sedefov & Gallegos, 2011). Methcathinone is synthesized from 
the oxidation of ephedrine, which is also a precursor for methamphetarnine (Maheux et 
al., 2010). Mephedrone is an analogue of methcathinone, which "is the ~-keto analog of 
methamphetamine and the N-methyl derivative of cathinone" (Maheux et al., 20 l 0, p. 
42). Because methcathinone is made from the same precursor of methamphetamine, and 
mephedrone is the analogue of methcathinone, this can explain why mephedrone has 
similar central nervous stimulatory effects as those of amphetamines. Mephedrone has 
recently been scheduled as a schedule I drug in the United States. 
Mephedrone, known as bath salts, appears as a white/slightly yellow powder or a 
tablet and is most commonly administered via insufflation, but it can also be administered 
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orally, smoked, or intravenously (Drugs of Abuse, 2011). When taken orally in its 
powder form, mephedrone is placed in cigarette paper and swallowed; this is referred to 
as bombing (Prosser & Nelson, 2012). Mephedrone users report that after insufflation, 
effects are experienced within 10 to 20 minutes and last about l to 2 hours. Users try to 
overcome the quick comedown of insufflation by taking multiple doses (Schifano et al., 
2011). The desired effects of oral ingestion occur after 15 to 45 minutes of ingestion and 
have duration of 2 to 4 hours (Prosser & Nelson, 2012). Because effects last longer with 
oral ingestion, the need to take more doses to maintain that high is less than that of 
insufflated mephedrone (Schifano et al., 2011 ). Users report that injection intravenously 
provides effects within 10 to 15 minutes and tend to last 30 minutes (Prosser & Nelson, 
2012). 
Mephedrone produces stimulatory and hallucinogenic effects like that of 
amphetamines and ecstasy, respectively. Although there are no published formal studies 
on the psychological effects of mephedrone on humans, users do report effects that are 
"broadly comparable to those reported for better-studied stimulant drugs" (Sedefov & 
Gallegos, 2011, p. 29). The effects reported by mephedrone users are those of "euphoria, 
general stimulation, enhanced music appreciation, elevated mood, decreased hostility, 
improved mental function and mild sexual stimulation" (Sedefov & Gallegos, 2011, p. 
29). Other than the desired pleasurable effects, users also experience adverse effects that 
vary from agitation, depression, paranoia, and panic attacks (Drugs of Abuse, 2011 ). 
Schifano et al. (2011) reported user complaints consisting of loss of appetite, nausea, 
headache, dizziness, anxiety, agitation, elevated blood pressure, chest pain, and difficulty 
urinating. 
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Despite mephedrone having become increasingly popular over the recent years, 
there is still much to be learned of its pharmacology and toxicity. A report from Sedefov 
and Gallegos (2011) speculate that mephedrone acts as other stimulants by blocking 
reuptake and stimulating the release of stimulant neurotransmitters such as serotonin, 
dopamine, and norepinephrine. Support of this speculation is based on its chemical 
structure and the similar sympathomimetic effects that are seen with mephedrone in 
comparison to other stimulant drugs such as MDMA and cocaine (Sedefov & Gallegos, 
2011). Martinez-Clemente, Escubedo, Pubill, and Camarasa (2012) determined that 
mephedrone interacts with the transporters of dopamine and serotonin and blocks the 
uptake of the neurotransmitters. The Encyclopedia of the Human Brain (2002) states that 
serotonin affects sleep, mood, sexual behavior, and aggressive behavior; dopamine is 
involved with the reward system and in addiction. Before studies on metabolism were 
conducted, it was figured that mephedrone is "partly excreted as glucuronides and 
sulphate conjugates" (Sedefov & Gallegos, 2011 , p. 58). Meyer, Wilhelm, Peters, and 
Maurer (2010) concluded from a study on mephedrone's metabolism in human and rat 
urine that mephedrone is partly excreted as glucuronides and/or sulfates. 
Synthetic cathinones are less potent than their phenethylamine analogues due to 
the ~-keto group increasing the polarity and allowing less chance for passage across the 
blood-brain barrier (Drug Profiles, 2012). Although less potent and structurally similar to 
amphetamines, there is still much more to be known about ring substituted cathinones. 
There have been numerous reports of mephedrone related deaths and admittance to the 
hospital for poisoning, but there is still no solid conclusion on the toxicity of 
mephedrone. A case reported by the American College of Medical Toxicology 
determined that a male who had ingested 200mg of mephedrone and intramuscularly 
injected 3.8g suffered from "isolated mephedrone toxicity" (Wood et al. , 2010, p. 329). 
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CHAPTER III 
METHODOLOGY 
Method Overview 
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Synthetic urine samples were used for the purposes of this research. Two 
milliliters of the synthetic urine were placed into 80 l 6x 120 screw cap tubes. Forty tubes 
of the synthetic urine were spiked with 20µL of mephedrone to make a concentration of 
0.5µg/mL; the remaining 40 tubes were spiked with 80µL, making a concentration 
2.0µg/mL. Forty samples, which consisted of 20 tubes of 0.5µg/mL mephedrone and 20 
tubes of 2.0µg/mL mephedrone, were extracted using liquid-liquid extraction (LLE). The 
remaining samples were extracted using solid phase extraction (SPE). Each extract was 
derivatized and injected into the Gas Chromatography-Mass Spectrometer (GC-MS) 
under specific parameters. Results of the GC-MS analysis were used to compare LLE 
and SPE to determine which method is more efficient. Spiked samples with 
concentrations of 0.25µg/mL, 0.125µg/mL, and 0.05µg/mL were analyzed to determine 
mephedrone ' s limits of detection for both extractions. Concentrations of 0.5µg/mL and 
2.0µg/mL were used as neat standards with which to compare the extracted samples. 
Preparation of Mephedrone Standard 
A Mephedrone-HCl (Cerilliant, Round Rock, TX) standard with a concentration 
of 1 mg/mL was used to make dilutions of standards with the following steps: 
1. lmL of lmg/mL mephedrone-HCl was added to a tube with 4mL of methanol 
(MeOH) and vortexed for approximately 5-10, seconds making a concentration 
of 200µg/mL. 
2. lmL of 200µg/mL mephedrone was pipetted into another tube with 3mL of 
MeOH to make 50µg/mL mephedrone. 
-13 
I 
Preparation of Neat Mephedrone Standard 
Mephedrone standards of 0.5µg/mL and 2.0µg/mL were used with which to 
compare analyzed extracts. The neat standards were prepared by the following steps: 
1. 2mL of MeOH were pipetted into two separate tubes. 
2. 20µL of 50µg/mL standard were pipetted into one tube. 
3. 80µL of 50µg/mL standard were pipetted into the other tube. 
4. l OOµL of 0.1 % HCl were added to each tube and vortexed. 
5. Each tube was place in a Rapidvap Labconco vacuum pump (Thermo-Fisher, 
Houston, TX) and evaporated to dryness at 50°C for approximately l hour. 
6. After drying, the standards were derivatized and dried again. 
7. Once dry, lOOµL of ethyl acetate were added to the standards and vortexed. 
8. The standards were transferred to autosampler vials containing 150µL inserts. 
9. Vials were labeled, capped, and placed on the GC-MS for injection. 
Preparation of Synthetic urine Samples 
1. 2mL of synthetic urine were pipetted into 86 16xl20 screw cap tubes. 
2. 20µL of the 50µg/mL standard were pipetted into 40 tubes containing 
synthetic urine and vortexed for a concentration of 0.5µg/mL. 
3. 80µL of the 50µg/mL standard were pipetted into 40 tubes containing 
synthetic urine and vortexed for a concentration of 2.0µg/mL. 
4. lOµL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic 
urine and vortexed for a concentration of 0.25µg/mL. 
5. 5µL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic 
urine and vortexed for a concentration of 0.125µg/mL. 
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6. 2µL of the 50µg/mL standard were pipetted into 2 tubes containing synthetic 
urine and vortexed for a concentration of 0.05µg/mL. 
Preparation of Sodium Hydroxide Solution 
A l .OM solution of sodium hydroxide (Fisher Scientific, Houston, TX) was added 
to the samples extracted via LLE to make the sample basic. The following steps were 
completed to prepare lOOmL of I.OM sodium hydroxide (NaOH) solution: 
1. 4. lg of NaOH were weighed out and placed into a 250mL Erlenmeyer flask. 
2. lOOmL of Type m water (Millipore, Billerica, MA) were measured with a 
graduated cylinder and added to the flask containing NaOH. 
3. The flask was swirled until NaOH had dissolved. 
Preparation of0.25M Phosphate Buffer 
A 0.25M phosphate buffer was used to prepare the samples before SPE. The 
phosphate buffer was prepared with both monobasic (NaH2P04) and dibasic (Na2HP04) 
sodium phosphate (Fisher Scientific, Houston, TX) by the following steps: 
1. 6.90g of NaH2P04 were weighed out and placed in a 200mL Erlenmeyer fl ask 
and dissolved to a final volume of 200mL with Type III water. 
2. 13.40g of Na2HP04 were weighed out and placed in a 200mL Erlenmeyer 
flask and dissolved to a final volume of 200mL with Type III water. 
3. lOOmL of the 200mL of NaH2P04 were added to a clean beaker and placed on 
a magnetic hot plate with a stirrer. 5mL of Na2HP04 were continuously added 
to the beaker until a pH of 6.0 was achieved. The pH of the solution was 
verified with a pH meter (Accumet 25CL, Fisher Scientific, Houston, TX). 
Preparation of 0.1 M Glacial Acetic Acid 
AO. lM solution of Glacial Acetic Acid (Fisher Scientific, Fair Lawn, NJ) was 
used with SPE for the washing of the sample. The following steps were completed to 
prepare lOOmL of the solution: 
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l. 1 OOmL of Type III water were measured with a graduated cylinder and poured 
into a l OOmL Erlenmeyer flask. 
2. 575µL of 17 .4M glacial acetic acid were pipetted into the flask. 
3. The flask was swirled for thorough mixing. 
Preparation of N-Butyl Chloride: Ethyl Acetate 
An 80:20 dilution of N-Butyl Chloride: Ethyl Acetate (Fisher Scientific, Fair 
Lawn, NJ) was used for both LLE and SPE to extract mephedrone. The solution was 
prepared by the following steps: 
l. 400mL of N-Butyl Chloride were measured using a graduated cylinder and 
poured into a 500mL Erlenmeyer flask. 
2. lOOmL of ethyl acetate were measured and poured into the flask containing N-
Butyl Chloride. 
3. The flask was swirled to allow the two to be mixed. 
Preparation of Triethylamine with N-Butyl Chloride: Ethyl Acetate 
Four percent Triethylamine (TEA) (Fisher Scientific, Fair Lawn, NJ) prepared 
with N-Butyl Chloride: Ethyl Acetate was used with SPE to elute the sample from the 
column. The solution was prepared by the following steps: 
1. 4mL of TEA were pipetted into a lOOmL volumetric flask. 
-2. N-Butyl Chloride: Ethyl Acetate (80:20) was added until the volume was 
brought to the l OOmL mark. 
3. The flask was covered and inverted several times to allow adequate mixing. 
Preparation of 0.1% Hydrochloric acid 
Hydrochloric acid (Fisher Scientific, Fair Lawn, NJ) was used for both methods 
of extraction during evaporation of the sample. Fifty milliliters of 0.1 % HCl were 
prepared as follows: 
l. 49.95mL of methanol were measured using a graduated cylinder and poured 
into a 1 OOmL Erlenmeyer flask. 
2. 50µL of 6M HCL were added to the flask. 
3. The flask was swirled for thorough mixing. 
Preparation of 10% Hydrochloric acid 
Hydrochloric acid was used to adjust the pH of the samples before SPE. The 
following steps were completed to prepare 10% HCl: 
l. A lOOmL volumetric flask was filled halfway with Type Ill water. 
2. lOmL of HCl were added to the flask. 
3. Type III water was added until the lOOmL mark was reached. 
Liquid-Liquid Extraction of Mephedrone 
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Forty-three spiked synthetic urine samples, 20 of 0.5µg/mL, 20 of 2.0µg/mL, 1 of 
0.25µg/rnL, 1 of 0.125µg/mL, and 1 of 0.05µg/mL were extracted via LLE by the 
following steps: 
l. lOOµL of l.OM NaOH solution were added to the sample and vortexed for 
approximate I y 5-10 seconds. 
2. 8mL of N-Butyl Chloride: Ethyl Acetate solution (80:20) were added to the 
sample and capped. 
3. The tubes were placed on a platform rotator for 30 minutes and mixed at a 
slow speed to prevent emulsion. 
4. The tubes were then centrifuged on a Sorvall Legend T + centrifuge (Fisher 
Scientific, Houston, TX) at 3000 RPM for 10 minutes. After 10 minutes of 
centrifuging, the tubes were bumped to remove the emulsion layer from the 
sides of the tube and centrifuged for another 10 minutes. 
5. The top layer containing N-Butyl Chloride: Ethyl Acetate was transferred to 
clean l 6x 120mm tubes. 
6. l OOµL of 0.1 % HCl were added to each sample and vortexed. 
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7. The samples were evaporated to dryness at 50°C for approximately l.5 hours. 
8. After drying, the samples were derivatized and dried again. 
9. Once dry, lOOµL of ethyl acetate were added to the samples and vortexed. 
10. The samples were transferred to autosampler vials containing 150µL inserts. 
11. Vials were labeled, capped, and placed on the GC-MS for injection. 
Solid Phase Extraction of Mephedrone 
Solid phase extraction was performed on "No Vacuum" Gravity GV-65C columns 
(Biochemical Diagnostics, Inc., Edgewood, NY). Forty-three spiked synthetic urine 
samples, 20 of0.5µg/mL, 20 of2.0µg/mL, 1 of0.25µg/mL, 1 of 0 .125µg/mL, and l of 
0.05µg/mL were extracted via SPE. 
.. 
Sample Preparation 
1. lmL of 0.25M sodium phosphate buffer (pH= 6) was added to each sample 
and vortexed. 
2. The samples were incubated at room temperature for 20 minutes. 
3. 200µL of 10% HCl were added to the samples to adjust the pH to 2. 
Column Conditioning 
1. 43 columns were set up to sit inside l 6x 120 tubes to allow proper gravity 
flow. 
2. lmL of MeOH was added to each column to wash the column. 
3. After the flowing of MeOH from the column, l mL of Type Ill water was 
added. 
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4. Extraction of the sample was followed within 20 minutes of column 
conditioning. 
Sample Extraction 
l. Each sample was poured onto a preconditioned column and allowed to flow 
through completely. 
2. 2mL of 0.1 M glacial acetic acid were added and allowed to flow through the 
column. 
3. 3mL of Type III water were added to wash the column. 
4. lmL of MeOH was added to the column. 
5. lmL of Ethyl Acetate was added to the column. 
6. Columns were dried at 40°C for 15minutes 
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Sample Elution 
1. Each column was placed into clean test tubes for the elution of the sample. 
2. l.5mL of N-Butyl Chloride: Ethyl Acetate (80:20) +4% Triethylamine were 
added to each column. 
3. 1 OOµL of 0.1 % HCl were add~d to each tube and vortexed. 
4. Each tube was evaporated to dryness at 50°C for approximately 1 hour. 
5. Once dry, the samples were derivatized and dried again. 
6. After drying, lOOµL of ethyl acetate were added to each tube and vortexed. 
7. The samples were transferred to autosampler vials containing 150µL inserts. 
8. Vials were labeled, capped, and placed on the GC-MS for injection. 
Derivatization of Dried Samples 
Before extracts were analyzed by GC-MS, the extracts were derivatized with 
Trifluoroacetic anhydride (TFAA) (Acros Organics, New Jersey, USA) by the following 
steps: 
1. lOOµL of TFAA were added to tubes containing dried extract. 
2. 500µL of Toluene (Acros Organics, New Jersey, USA) were added to the 
tubes, capped and vortexed. 
3. The tubes were heated with caps on at 70°C for 30 minutes. 
4. After heating, the tubes were allowed to cool for approximately 10 minutes. 
5. The samples were uncapped and allowed to dry at 70°C for approximately 1.5 
hours. 
---
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CC-MS Analysis 
Analysis was performed on a Perkin Elmer Clarus 600 Et AutoSystem GC with 
built-in Autosampler (Shelton, CT). 
CC Parameters 
Autosampler Method 
Syringe Capacity: 5.0µL 
Injection: Auto 
Injection Speed: Normal 
Viscosity Delay: 0 
Pre-Injection Solvent Washes: 2 
Post-Injection Solvent Washes: 8 
Injection Volume: 2µL 
Sample Pumps: 2 
Wash/Waste Vial Set: 1 
Pre-Injection Sample Washes: l 
Carrier Parameters 
Carrier Control: He 
Capillary column: MS5 30m x .25mm x 250µm phase 
Vacuum Compensation: On 
Flow Rate: 0.75mUmin 
Initial Hold: 999.0 min 
Heated Zones 
Inlet A: CAP 
Setpoint: 250°C 
Oven Program 
Cryogenics: Off 
Initial Temperature: I00°C 
Maximum Temperature: 275°C 
Initial Hold: 3.00 min 
Equilibration Time: 0.3 min 
Ramp: 25°C/min to 275°C, hold for O.Omin 
Timed Events 
Split 1: 0 at -0.20min 
Split 2: 50 at 0.30min 
MS Parameters 
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The MS analysis was performed on a PerkinElmer Clarus 600 Mass Spectrometer 
(Shelton, CT). 
Duration: 10.0 minutes 
Solvent Delay Start: O.Omin 
Solvent Delay End: 6.80min 
Number of Functions: 1 
Function 1: SIR of 3 masses 
Time: 7 .00 to 8.50 minutes 
Ion Mode: Er 
Scan Time: 0.25 seconds 
Inter Scan Delay: 0.005 seconds 
Channel 
1 
2 
3 
Mass (Da) 
91 
119 
154 
Dwell (s) 
0.050 
0.050 
0.050 
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CHAPTER IV 
DAT A AND RESULTS 
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A total of 86 tubes containing 2mL of synthetic urine were spiked with 
mephedrone and used for this research. Forty of the samples were spiked with 20µL of 
mephedrone for a concentration of 0.5µg/mL. The other forty were spiked with 80µL of 
mephedrone for a concentration of 2.0µg/mL. The six remaining synthetic urine samples 
were spiked with 10, 5, and 2µL of mephedrone to make two concentrations of 0.25, 
0.125, and 0.05µg/mL, respectively. An average retention time of 7.69 was seen for the 
majority of the extractions. 
Neat standards of mephedrone were analyzed to compare to the mean area and 
heights of extracted mephedrone to determine each method's percent recovery. The 
standards were prepared with 2mL of MeOH in each tube and 20µL and 80µL for 
concentrations of 0.5µg/mL and 2.0µg/mL, respectively. The samples were dried with 
I OOµL of 0.1 % HCl at 50°C. Each standard was derivatized, dried at 70°C for about 1.5 
hours, and analyzed by GC/MS using selective ion monitoring of the 91, 119, and 154 ion 
fragments (see Figure 4). The mean, standard deviation, and standard error for the 
standard concentrations were calculated using the peak area and height of the 119 ion 
fragment (Tables 1 and 2). Two standards' chromatograms are displayed in Figures 2 
and 3, showing areas and heights. 
.... 
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Table 1 
Mephedrone 119 Jon Area and Height of 0.5µg/ml Standard 
0.5µg/mL Sample No. 0.5µg/mL Area 0.5µg/mL Height 
l 33,231 1,482,680 
2 26,553 1,268,893 
3 2 1,787 996,368 
4 2 1,798 1,025,897 
5 53,249 2,929,822 
6 28,639 1,508, 190 
7 17,722 835,784 
8 25,698 1,307,290 
9 12,485 599,602 
10 18,1 15 833,576 
11 35,276 1,324,995 
12 33,109 1,434,687 
13 55,969 2,755,932 
14 29,986 1,431,726 
15 25,500 1,168,998 
16 26,372 1,266,032 
17 24,704 1,227,282 
18 32,633 1,682,028 
19 44,487 2,45 1,025 
20 44,310 2,423,222 
Mean: 30,58 1.1 50 1,497,701.450 
Std. Deviation: 1148 1.975 647,064.558 
Std. Error: 1862.622 104,967.732 
Note: Data for Standard 0.5µg/mL area and height of the 119 ion fragment. Results were used to determine percent recovery of LLE 
and SPE. 
LX Mean=-N 
- 2 
Standard Dev. = r cx-X) (N- 1) Est. Std. Error = so J(N1-l)+ (N2-l) 
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Table 2 
Mephedrone 119 Ion Area and Height of2.0µg/mL Standard 
2.0µg/rnL Sample No. 2.0µg/rnL Area 2.0µg/mL Height 
1 214,484 12,642,950 
2 165,478 9,734,338 
3 136,548 7,589,207 
4 119,981 6,516,962 
5 96,626 5,493,307 
6 150,156 8,841,016 
7 94,8 13 5,227,638 
8 219,481 13,192,626 
9 150,330 9,049,646 
10 122,241 7,185,256 
11 229,9 14 13,892,811 
12 100,121 5,447,835 
13 83,749 4,444,461 
14 185,437 11,349,705 
15 9 1,256 5,040,195 
16 184,296 11 ,048,184 
17 2 14,065 12,976,743 
18 109,247 6, 127,039 
19 206,177 12,104,322 
20 176,544 10,598,386 
Mean: 152,547.200 8,925,131.350 
Std. Deviation: 48,997.616 3,147,659.834 
Std. Error: 7,948.463 510,617.852 
Note: Data for Standard 2.0 µ g/mL area and height of the 119 ion fragment. Results were used to determine percent recovery of LLE 
and SPE. 
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Figure 2. Mephedrone chromatogram of neat standard 0.5µg/mL. Mephedrone was 
eluted from the column at 7 .69 minutes. The peak integration shows an area of 33,231 
and a height of 1,482,680. 
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Figure 3. Mephedrone chromatogram of neat standard 2.0µg/mL. Mephedrone was 
eluted from the column at 7 .69 minutes. The peak integration shows an area of 214,484 
and a height of 12,642,950. 
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Figure 4. TFAA derivatized Mephedrone ion spectra displaying the 119 ion fragment 
which used for peak integration. 
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LLE were performed on 20 of the 0.5µg/rnL, 20 of the 2.0µg/rnL, and 1 of each of 
0.25µg/mL, 0.125µg/rnL, and 0.05µg/rnL. Each sample was treated with lOOµL of 
NaOH to adjust the pH before extraction with 8rnL of N-Butyl Chloride: Ethyl Acetate 
(80:20). The samples were placed on a platform rotator for 30 minutes and followed by 
centrifugation for a total of 20 minutes. Halfway between centrifugation, the samples 
were removed and bumped to remove the emulsion layer from the walls of the tube. 
After centrifugation, the extraction solvent was removed and added to clean test tubes. In 
order to reduce the loss of sample during evaporation, lOOµL of 0.1 % HCI was added to 
each sample. The extraction solvent was dried completely before derivatization at 70°C 
for 30 minutes with 1 OOµL of trifluoroacetic anhydride (TFAA) and 500µL of toluene. 
The samples were dried and analyzed by GC-MS using selective ion monitoring of the 
91 , 119, and 154 ion fragments. The mean, standard deviation, and standard error for 
LLE of 0.5µg/rnL and 2.0µg/mL were calculated using the peak area and height of the 
119 ion fragment (see Tables 3 and 4). 
Table 3 
Mephedrone 119 lon Area and Height of0.5µglml LLE 
0.5µg/mL Sample No. 119 ion area 119 ion height 
1 582 37,357 
2 1,721 100,837 
3 2,187 108,700 
4 2,643 154,168 
5 1,299 73,387 
6 1,499 79,785 
7 5,444 305,602 
8 990 48,175 
9 2, 179 113,124 
10 1,337 72,075 
11 2,42 1 137,473 
12 2,642 14 1,901 
13 4,730 263,716 
14 3,257 180,919 
15 2,847 160,735 
16 2,978 175,193 
17 3,497 194,397 
18 2,955 172,803 
19 2,143 124,263 
20 5,176 287,616 
Mean: 2626.350 146611.300 
Std. Deviation: 1324.717 74819.919 
Std. Error: 214.898 12137.394 
Note: Data fo r LLE of 0.5µ g/mL area and height of the l l 9 ion fragment. Results were used to establish any significant difference 
compared to SPE. 
- 2 
Standard Dev. = l:(X-X) (N-1) Std. Error = -;==
5
=
0
= = J(N1 -l)+(Nz-1) 
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Table 4 
Mephedrone 119 Ion Area and Height of2.0µg/mL LLE 
2.0µg/mL Sample No. 119 ion area 119 ion height 
l 5289 376,515 
2 21,618 1,124,926 
3 29,385 1,577,971 
4 34,932 1,863,275 
5 32,404 1,788,215 
6 35,050 1,903,884 
7 83,053 4,649,702 
8 106,410 6,243,251 
9 55,559 2,993,259 
10 150,682 8,605,144 
11 209,051 11 ,926,742 
12 88,895 4,806,430 
13 84,467 4,502,916 
14 195,287 10,462,803 
15 177,427 9,9 15,483 
16 225,729 12,308,8 18 
17 227,575 13,088,955 
18 209,289 11,666,571 
19 169,992 9,269,243 
20 193,712 10,624,808 
Mean: 116790.300 6484945.550 
Std. Deviation: 78604.595 4400128.071 
Std. Error: 12751.349 713795.029 
Note: Data for LLE of 2.0µg/mL area and height of the 11 9 ion fragment. Results were used to establish any significant difference 
compared to SPE. 
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SPE were performed on the remaining samples: 20 of the 0.5µg/mL, 20 of the 
2.0µg/mL, and 1 of each of 0.25µg/mL, 0.125µg/mL, and 0 .05µg/mL. One mL of l .OM 
sodium phosphate buffer (pH = 6) was added to each sample and incubated at room 
temperature for 20 minutes. To acidify the sample before extraction, 200µL of 10% HCl 
was added to each sample. The samples were poured onto columns that were 
preconditioned with lmL of MeOH and lmL of type III water. The samples were 
washed with 2mL of O. lM glacial acetic acid, 3mL of type Ill water, lmL of MeOH, and 
lmL of ethyl acetate, allowing for each solvent to flow through completely. The columns 
were dried at 40°C for 15 minutes. To elute the samples, l.5mL of N-Butyl Chloride: 
Ethyl Acetate + 4% TEA were added to each column. One hundred microliters of 0.1 % 
HCl was added to the eluent and evaporated to dryness at 50°C for l hour. The dried 
samples were derivatized at 70°C for 30 minutes with lOOµL of trifluoroacetic anhydride 
(TFAA) and 500µL of toluene. The samples were dried and analyzed by GC-MS using 
selective ion monitoring of the 91, 119, and 154 ion fragments. The mean, standard 
deviation, and standard error for SPE of 0.5µg/mL and 2.0µg/mL were calculated using 
the peak area and height of the 119 ion fragment (see Tables 5 and 6). 
r 
Table 5 
Mephedrone 119 Jon Area and Height of0.5µ g/mL SPE 
0.5µg/mL Sample No. 11 9 ion area 119 ion height 
1 1,967 153,399 
2 6,217 362,220 
3 3,093 183,960 
4 5,563 341,736 
5 3,425 197,614 
6 3, 138 186,997 
7 2,985 177,646 
8 5,014 312,828 
9 4,255 266,559 
10 6,39 1 397,219 
11 3,841 235,206 
12 6,444 41 1,544 
13 3,981 243,242 
14 4,4 11 265,679 
15 2,722 159,094 
16 6,165 383,4 12 
17 3,22 1 191,361 
18 5,533 340,534 
19 3,797 229,480 
20 4,562 274,576 
Mean: 4336.250 2657 15.300 
Std. Deviation: 1352.750 83645.771 
Std. Error: 2 19.445 13569.1 36 
Note: Data for SPE of 0.Sµg/mL area and height of the 119 ion fragment. Results were used to establish any significant difference 
compared to LLE. 
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Table 6 
Mephedrone 119 Ion Area and Height o/2.0µg/ml SPE 
2.0µg/mL Sample No. 119 ion area 119 ion height 
1 17,539 966,463 
2 34,427 1,958,788 
3 33,617 2,035,855 
4 21,767 1,310,7 13 
5 33,940 2,040,852 
6 19,630 1,153,008 
7 15,088 894,503 
8 18,993 1,138, 131 
9 22,368 1,385,448 
10 21,823 1,304,416 
11 22,081 1,353,607 
12 28,125 1,749,587 
13 17,402 1,043,270 
14 7,507 450,643 
15 28,346 1,646,558 
16 25,874 1,612, 155 
17 25,486 1,575,600 
18 31,485 1,875,417 
19 27,544 1,647,794 
20 28,237 1,739,522 
Mean: 24063.950 1444116.500 
Std. Deviation: 6977.600 421209.818 
Std. Error: 1131.916 68329.255 
Note: Data for SPE of 2.0µg/mL area and height of the 119 ion fragment. Results were used to establish any significant difference 
compared to LLE. 
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Concentrations of 0.25µg/mL, 0.125µg/mL, and O.OSµg/mL were extracted via 
LLE and SPE to determine mephedrone's limit of detection for each method (see Tables 
7 and 8). 
Table 7 
Mephedrone 119 Ion Area and Height of LLE 0.25µg/mL, 0. 125µg/mL, and 0.05µglmL 
Concentration of Sample 
0.25µg/mL 
0.125µg/mL 
O.OSµg/mL 
119 Ion Area 
5,834 
2,727 
2,523 
119 Ion Height 
327,251 
135,488 
134,183 
Note: Data of LLE of 0.25µg/mL. O. l 25µ g/mL and 0.05µg/mL to determine mephedrone's li mit of detect.ion for LLE. 
Table 8 
Mephedrone 119 Ion Area and Height of SPE 0.25µ glmL, 0. 125µg/mL, and 0.05µ g/mL 
Concentration of Sample 119 Ion Area 119 Ion Height 
0.25µ g/mL 1,489 98,848 
0. 125µg/mL 572 
38,432 
O.OSµ g/mL 16 1 9,897 
Note: Data of SPE of 0 .25µg/mL. O. l 25µg/mL. and 0.05µg/mL to determine rnephedrone·s li mit of detection for SPE. 
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To determine if there was a statistical difference between LLE and SPE, a t test 
was completed at the .05 level of confidence. The standard error of difference for area 
and height of both concentrations and methods was calculated and used to determine a t 
ratio. Compared to at value of 2.086, the t ratio was outside of the 0.5 confidence level, 
signifying that LLE and SPE are significantly different (see Tables 9 and 10). 
Table 9 
Statistical Comparison of LLE and SPEfor 0.5µ g/mL 
Mean Standard Error Standard Error of Difference f(.05)(100) 
LLE Area 2626.35 
SPE Area 4336.25 
LLE Height 146611.30 
SPE Height 265715.30 
214.898 
219.445 
12137.394 
13569.136 
307.143 
18205.433 
5.567 
6.542 
Note: Statistical comparison of 0.5µg/mL LLE and SPE. With a degree of freedom of 19. the I value is 2.086. The t ratios fo r 
0.5µg/mL are larger than the I value , meaning that LLE and SPE are significantly different for this concentration. 
Std. Error Difference = j (SE1 2 + SE2 2) 
r 
T 
Table 10 
Statistical Comparison of LLE and SPE for 2.0µg/mL 
LLE Area 
SPE Area 
Mean 
116790.30 
24063.95 
LLE Height 6484945.55 
SPE Height 1444116.50 
Standard Error Standard Error of Difference t(.OS)( IOO) 
12751.349 
1131.916 
713795.029 
68329.255 
12801.490 7.243 
717058.038 7.030 
Note: Statis tical comparison of 2.0µg/mL LLE and SPE. With a degree of freedom of 19. the t value is 2.086. The t ratios fo r 
2.0µg/mL are larger than the I value. meaning that LLE and SPE are significantly different for this concentration. 
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Percent recovery shows the percentage of analyte that is recovered from each 
method based off of the samples ' peak area and height. Peak integration was performed 
on the 119 ion fragment to provide the samples' area and height. The average of 
0.5µg/mL and 2.0µg/mL area and height for both methods were compared to 
mephedrone's average standard area and height to achieve a percentage (Tables 11 and 
12) 
Table 11 
Percent Recovery for 0.5µ glmL Mephedrone Extraction 
Standard Area 
LLE Area 
SPE Area 
Mean 
30581.15 
2626.35 
4336.25 
Percent Recovery 
8.59% 
14.18% 
Table 11 (continued.) 
Standard Height 
LLE Height 
SPE Height 
Mean 
1497791.45 
146611.30 
265715.30 
Percent Recovery 
9.79% 
17.74% 
Note: Percent recovery of 1 19 ion fragment for LLE and SPE of 0.5µg/mL. SPE has a higher percentage of recovery than LLE: 
therefore, SPE is a more effi cient method for 0.5µg/mL mephedrone. 
(
Extraction~ Percent Recovery= d d x 100 Stan ar X 
Table 12 
Percent Recovery f or 2.0µ g/ml Mephedrone Extraction 
Standard Area 
LLE Area 
SPE Area 
Standard Height 
LLE Height 
SPE Height 
Mean 
152547.20 
116790.30 
24063.95 
8925131.35 
6484945.55 
1444116.50 
Percent Recovery 
76.56% 
15.77% 
72.66% 
16.18% 
Note: Percent recovery of 119 ion fragment fo r LLE and SPE of2.0µg/ mL. LLE has a higher percentage of recovery than SPE: 
therefore. LLE is a more efficient method for recovery of 2.0µg/mL mephedrone. 
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CHAPTER V 
DISCUSSION 
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Mephedrone is currently one of the more popular designer drugs of today. Its 
stimulatory and hallucinogenic effects provide a high like that of amphetamines and 
ecstasy. With its increasing popularity, it is imperative that efficient methods of analysis 
are employed in an attempt to keep up with the designer world. This study was 
conducted with goals of confirming that one method of extraction is more efficient and 
conducive to obtaining knowledge of mephedrone 
Liquid-liquid extraction is the oldest and most widely used method of extraction. 
The use of two immiscible liquids appears to be fairly simple, but can be time consuming 
and costly due to the large amounts of solvents used. Although not as old in the scientific 
world as LLE, solid phase extraction involves the use of columns and smaller amounts of 
solvents. 
In this research, the derivatization of mephedrone prior to analysis proved to be a 
crucial step in detecting the analyte from the extracts. Initially LLE and SPE were 
conducted on all synthetic urine samples, with no success for SPE. LLE analysis 
detected mephedrone and displayed peaks that could be integrated. SPE, however, gave 
distorted chromatograms with no ability to identify mephedrone. Derivatization was 
applied to help identify mephedrone because of is small molecular weight of 
177.242g/mol. 
This experiment focused on determining the more efficient method for the 
extraction of mephedrone from synthetic urine. It was theorized that LLE would be the 
more efficient method compared to SPE in the recovery of mephedrone. Because 
mephedrone is a designer drug, there was concern that the use of columns specified for 
amphetamine drug testing may not be successful. After numerous trial runs, SPE 
demonstrated its ability to extract mephedrone just as LLE method. Manufacturer's 
directions did not specify to dry the columns prior to elution of the sample, but this 
technique was the determining factor in GC-MS detecting mephedrone from SPE 
extracts. 
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Eighty mephedrone spiked synthetic urine samples were extracted; 20 of 
0.5µg/mL and 20 of 2.0µg/mL were extracted via LLE and 20 of 0.5µg/mL and 20 of 
2.0µg/mL were extracted via SPE. A two tail T-test was completed on the average areas 
and heights of the analyzed samples. The t ratio of area and height of each extraction 
were compared to at value of 2.086 with a confidence level of .05 and 19 degrees of 
freedom. The t ratios for LLE and SPE of 0.5µg/mL were 5.567 and 6.542 for area and 
height respectively. For LLE and SPE of 2.0µg/mL, the t ratio was calculated to 7 .243 
for area and 7 .030 for height. The t ratios for both extractions and concentrations falling 
under the t value signify that LLE and SPE are significantly different for the extraction of 
mephedrone. 
The areas and heights of the analyzed samples were used to determine which 
method was more efficient in recovering mephedrone from synthetic urine. Standards of 
0.5µg/mL and 2.0µg/mL that were not extracted, were derivatized and analyzed 20 times 
each just as the extracts were. The results of the standards' areas and heights were 
compared to the average areas and heights of the extracted samples of both methods. The 
results concluded that for 0.5µg/mL, SPE is more efficient with a recovery of 14.18% and 
17.74% for area and height compared to LLE 8.59% and 9.79%. For 2.0µg/mL, LLE 
39 
percent recovery is better than that of SPE. LLE percent recovery for area and height are 
76.56% and 72.66% while SPE percentages are 15.77% and 16.18%. 
Additional samples of 0.25, 0.125, and 0.05µg/mL were extracted via both LLE 
and SPE to determine mephedrone's limit of detection with analysis of GC-MS. For 
LLE, a steady decrease in peak area and height is seen with the decreasing 
concentrations. SPE peak area and height also show an area and height decrease with 
decreasing concentration. The peak areas and heights are smaller for SPE than LLE. In 
both cases, mephedrone is still detected at only 0.05µg/mL. For toxicological purposes, 
there is no need to test lower than this limit. 
There is a large variation in the data received, which may be due to inconsistent 
derivatization of the extract. Capacity limits of SPE gravity flow columns may present an 
issue as well for extracting concentrations beyond 0.5µg/mL. Research would need to be 
conducted to determine the capacity of this column. The factor of varying results may 
have been able to be pinpointed had an internal standard been used in this research. In 
this study, however, there were issues with obtaining an appropriate internal standard for 
extraction of mephedrone. In the areas of derivatization, column capacity, and use of an 
internal standard, further research is needed. 
This study exhibited that for the extraction of mephedrone spiked synthetic urine, 
SPE is a better extraction method than LLE in the case of extracting concentrations lower 
than 2.0µg/mL. If extracting larger concentrations of 2.0µg/mL and beyond, LLE 
appears to be the better method. Although both methods serve the same purpose of 
extracting analytes from mediums, they are significantly different. Further studies on this 
research would be beneficial to analysts to ensure they are getting the most out of their 
analysis as well as to the human performance arena of forensic toxicology. 
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